Home > Boards > US Listed > Miscellaneous > Astrotech Corp. (ASTC)

NEWSAstrotech’s BreathTest-1000 Confirmed to Detect Lung Disease Metabolites

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Mr Fox Member Profile
 
Followed By 8
Posts 516
Boards Moderated 0
Alias Born 01/29/15
160x600 placeholder
Astrotech Announces Pricing of $18.0 Million Upsized Public Offering Business Wire - 10/21/2020 1:15:00 PM
Registration of Additional Securities (up to 20%) (s-1mef) Edgar (US Regulatory) - 10/21/2020 1:08:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/20/2020 5:23:35 PM
Astrotech Subsidiary and Cleveland Clinic Partner to Develop a Rapid COVID-19 Breath Test Business Wire - 10/20/2020 4:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2020 4:46:39 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 9/14/2020 7:39:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2020 12:09:50 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 9/9/2020 3:53:01 PM
1st Detect’s Tracer 1000™ Achieves Milestone in TSA Air Cargo Screening Qualification Test Business Wire - 9/9/2020 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/8/2020 3:59:11 PM
Annual Report (10-k) Edgar (US Regulatory) - 9/8/2020 3:51:43 PM
Astrotech Reports Fiscal Year 2020 Financial Results Business Wire - 9/8/2020 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/26/2020 10:30:54 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 7/6/2020 4:46:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 3:37:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/29/2020 3:07:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2020 3:55:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2020 4:48:27 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/13/2020 12:35:57 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/12/2020 2:25:53 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/24/2020 4:32:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/20/2020 4:53:55 PM
Astrotech Announces Closing of $3.27 Million Registered Direct Offering Priced At-the-Market Business Wire - 3/30/2020 2:50:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/30/2020 7:43:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/30/2020 7:39:32 AM
Mr Fox   Friday, 03/27/20 09:18:53 AM
Re: dinogreeves post# 2781
Post # of 2900 
NEWS
Astrotech’s BreathTest-1000 Confirmed to Detect Lung Disease Metabolites at Parts Per Billion
AUSTIN, Texas--(BUSINESS WIRE)-- Astrotech Corporation [NASDAQ: ASTC] announced that the BreathTest-1000™ lung disease screening device that is under development detects a known metabolite that is associated with lung diseases at very low parts per billion (ppb) concentrations. On March 25, the Company announced that it is working on developing the BreathTest-1000™ to detect volatile organic compound metabolites present in lung diseases such as the Coronavirus (“COVID-19”) and pneumonia.

“The Company just reached a milestone in its vision of providing what it believes to be a highly accurate field instrument that, subject to applicable regulatory approval, may provide lung disease testing worldwide. Today’s news is exciting because it accelerates the development process of the BreathTest-1000™ and we believe gets us closer to joining the front-line in the fight against lung diseases, such as COVID-19,” stated Thomas B. Pickens III, Chairman and Chief Executive Officer of Astrotech Corporation.

“The Company was able to move quickly in the development of the BreathTest-1000™ because the core mass spectrometry technology it utilizes has been fully commercialized and deployed for explosives trace detection. Our goal is to satisfy all regulatory requirements for the BreathTest-1000™ as rapidly as possible once the necessary application developments are completed. We believe that few, if any, changes will need to be made to the underlying technology. We plan to devote our efforts towards developing a simple and consistent sample introduction system,” Mr. Pickens concluded.




Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences